FcRn 억제제 : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• Neonatal fragment crystallizable (Fc) receptor (FcRn), also known as the Brambell receptor, is the major histocompatibility complex (MHC) I-related receptor encoded by the FCGRT gene. In the 1960s, Brambell was the first to propose that there might be a receptor capable of mediating the transport of IgG from mother to infant.
• FcRn inhibitors are effective treatments for myasthenia gravis, thyroid eye disease, and other indications like bullous pemphigoid, chronic inflammatory demyelinating polyneuropathy, warm autoimmune hemolytic anemia, Graves' disease, and many more indications.
• Several companies, including Johnson & Johnson Innovative Medicine, UCB Biopharma, Pfizer, and Viridian Therapeutics, are engaged in the development of FcRn inhibitors, with many approved and emerging drugs.
• In the myasthenia gravis market, Efgartigimod alfa is leading with established dominance and potential expansion into indications like myasthenia gravis with the trial ADHERE. It is the largest randomized controlled trial of any CIDP treatment to date. It supports the role of pathogenic autoantibodies in CIDP pathology.
• In the full year 2023, the global net product revenues generated by VYVGART and VYVGART SC were USD 908 million and USD 246 million respectively.
• In March 2024, Johnson & Johnson (J&J) obtained fast-track designation from the US Food and Drug Administration (FDA) for its nipocalimab to reduce foetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in alloimmunised pregnant adults.
• FcRn inhibitors have the potential to meet an urgent need for a more targeted therapeutic approach to pathogenic IgG reduction and provide a less invasive and time-consuming alternative to PLEX, IA, and immunomodulatory high-dose IVIg therapies.

DelveInsight's "FcRn inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2036" report delivers an in-depth understanding of the FcRn inhibitor, historical and Competitive Landscape as well as the FcRn inhibitors' market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The FcRn inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM FcRn inhibitor market size from 2020 to 2034. The report also covers current FcRn inhibitor treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2022-2036

FcRn Inhibitors Disease Understanding and Treatment Algorithm

FcRn Inhibitors Overview

The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling mechanism to prevent degradation and extend the half-life of IgG and albumin in circulation. FcRn plays a crucial role in the maintenance of IgG levels by salvaging IgG from lysosomal degradation, thereby prolonging its half-life. In non-human primates, anti-FcRn antibodies reduced IgG levels by over 60%, without significant, concomitant changes in the serum content of albumin, IgA, or IgM. FcRn inhibitors are anti-FcRn monoclonal antibodies with high affinity for FcRn at both neutral and acidic pH. Inside the cell, FcRn inhibitors compete with IgG for binding to FcRn. Because of their higher affinity, FcRn inhibitors prevent IgG from binding to FcRn, and IgG is transported to the lysosome and degraded, which leads to a decrease in circulating IgG levels. FcRn: Neonatal Fc receptor; IgG: immunoglobulin G.

FcRn Inhibitors Market Overview

Neonatal Fc receptor-targeted therapies are engineered to selectively target FcRn through various methods, such as Fc fragments or monoclonal anti-FcRn antibodies. These approaches enhance the breakdown of autoantibodies by blocking the immunoglobulin G recycling pathway. This mechanism reduces overall plasma immunoglobulin levels, including the levels of pathogenic autoantibodies, without affecting the other immunoglobulin classes immunoglobulin a, immunoglobulin E, immunoglobulin M, and immunoglobulin D levels. Drugs that inhibit FcRn include efgartigimod, rozanolixizumab, batoclimab, and nipocalimab. These medications can be administered either intravenously or subcutaneously. Numerous clinical trials are currently underway to investigate their effectiveness, safety, and tolerability in various neurological conditions, including myasthenia gravis and other neurological disorders such as chronic inflammatory demyelinating polyneuropathy, myositis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. Positive results from clinical trials of efgartigimod and rozanolixizumab led to their approval for the treatment of generalized myasthenia gravis. Additional clinical trials are still ongoing.

FcRn Inhibitors Epidemiology

The FcRn inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indications for FcRn inhibitors, total eligible patient pool of selected indication for FcRn inhibitors, total treated cases in selected indications for FcRn inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2022 to 2036.

• In 2023, chronic inflammatory demyelinating polyneuropathy (CIDP) affected approximately 21,000 patients in the United States.
• Graves' disease had an estimated prevalence of around 1,241,720 cases across the EU4 and the UK in 2023.
• Thyroid eye disease impacted approximately 84,000 patients across the seven major markets (7MM) in 2023.

FcRn Inhibitor Drug Chapters

The drug chapter segment of the FcRn inhibitor reports encloses a detailed analysis of approved FcRn inhibitors late-stage (Phase III and Phase II) FcRn inhibitors. It also helps understand the FcRn inhibitor's clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

VYVGART (Efgartigimod): Argenx

Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). It is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, and IgG autoantibodies, where a severe unmet medical need exists. Efgartigimod's subcutaneous form is coformulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE drug delivery technology, which allows for subcutaneous delivery of biologics that are typically administered via infusion. In December 2021, it was approved by the FDA for Generalised Myasthenia Gravis. It is in the pipeline for various other indications including thyroid eye disease, Myositis, and many more diseases.

RYSTIGGO (rozanolixizumab-noli): UCB Biopharma

It is a high-affinity humanized immunoglobulin G4 monoclonal antibody directed against human neonatal Fc receptor (FcRn). It is administered subcutaneously. It received its first approval on 27 June 2023 in the USA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. Rozanolixizumab is the first agent to be approved in the USA for both anti-AChR and anti-MuSK antibody-positive gMG. A regulatory assessment of rozanolixizumab for the treatment of gMG is currently underway in the EU and Japan. Clinical development is ongoing for the treatment of leucine-rich glioma-inactivated 1 autoimmune encephalitis, myelin oligodendrocyte glycoprotein (MOG) antibody disease, and severe fibromyalgia syndrome.

Emerging Drugs

Batoclimab: Immunovant

Batoclimab is an investigational, fully human monoclonal antibody developed by Immunovant that targets FcRn to reduce pathogenic IgG autoantibodies in autoimmune diseases. Early studies have shown up to 78% IgG reduction, supporting its biological potency. Administered subcutaneously with potential for self-administration, batoclimab is being evaluated in multiple high-unmet-need indications, including myasthenia gravis, thyroid eye disease, CIDP, and Graves' disease. Global Phase III clinical trials of batoclimab in myasthenia gravis and thyroid eye disease (TED) progressing and on track.

In December 2023, Immunovant announced that results from the initial cohort of patients in an ongoing 24-week Phase II clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.

In March 2025, Immunovant reported topline results from its Phase III study of batoclimab in myasthenia gravis and initial results from Period 1 of its Phase IIb study in CIDP, and Immunovant anticipates sharing topline results from both TED studies.

IMVT-1402: Immunovant

Immunovant had received IND clearance for IMVT-1402 from the US FDA. It is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases. In the initial results of a Phase I clinical trial in healthy adults, IMVT-1402 demonstrated favorable pharmacodynamic and safety data. These attributes, combined with a convenient route of administration that may enable patient self-administration, position IMVT-1402 well as a potential treatment for a variety of autoimmune diseases associated with patient unmet need.

IMVT-1402 development is progressing with potentially registrational studies in Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjogren's disease (SjD) remains on track.

Immunovant expects to report results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and topline results from the proof-of-concept trial of IMVT-1402 in Cutaneous lupus erythematosu (CLE) in calendar year 2026.

Recent Developments in the FcRn Inhibitors Market

• In March 2026, Johnson & Johnson announced that the U.S. FDA had granted Fast Track status to nipocalimab for the potential treatment of adult patients with systemic lupus erythematosus (SLE).
• In February 2026, argenx SE announced encouraging topline results from its Phase 3 ADAPT OCULUS study investigating VYVGART for adults diagnosed with ocular myasthenia gravis.
• In January 2026, argenx SE announced that the FDA had granted priority review to a supplemental Biologics License Application (sBLA) for VYVGART, seeking approval for its use in adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).
• In January 2026, Johnson & Johnson reported encouraging topline findings from the Phase 2b JASMINE (NCT04882878) trial involving adults with Systemic Lupus Erythematosus, and has begun advancing the therapy into a Phase 3 clinical development program.
• In December 2025, Johnson & Johnson announced that the European Commission granted Marketing Authorisation for IMAAVY (nipocalimab) as an add-on therapy for gMG in adults and adolescents aged twelve years and older who are anti-AChR or anti-MuSK antibody-positive.

FcRn Inhibitor Market Outlook

The market for FcRn inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with wAIHA, systemic lupus erythematosus, Graves disease, thyroid eye disease, and many more indications; the growing awareness of FcRn inhibitors, and the increasing number of emerging drugs that are under clinical trials and filed for approval by various companies.

The greater affinity of FcRn has adverse effects on IgG-mediated autoimmune diseases like rheumatoid arthritis, myasthenia gravis, or pemphigus vulgaris. Targeting FcRn and inhibiting FcRn circulation can improve IgG catabolism, resulting in reduced IgG and pathogenic autoantibody levels, which is anticipated to decrease all autoimmune abnormalities induced by IgG. There are many drugs in the pipeline like Nipocalimab and Batoclimab, that are being developed to target FcRn to cure various indications like Myasthenia gravis, thyroid eye disease, CIPD, and many more. Drugs like VYVGART and RYSTIGGO have received FDA approval for Myasthenia gravis and are in the pipeline for other indications.

Several key players, including ArgenX, UBC Biopharma, Pfizer, and others, are involved in developing drugs for FcRn inhibitors for various indications such as myositis, myasthenia gravis, fibromyalgia, systemic lupus erythematosus, and others. Overall, this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of FcRn inhibitors and define their role in the therapy of autoimmune and neurological disorders.

FcRn inhibitor Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging FcRn inhibitors expected to be launched in the market during 2022-2036.

FcRn Inhibitor Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for FcRn inhibitors market growth over the forecasted period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for FcRn inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on FcRn inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Johns Hopkins Sidney Kimmel Cancer Center and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or FcRn inhibitor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the FcRn inhibitor, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the FcRn inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM FcRn inhibitor market.

FcRn Inhibitor Report Insights

• FcRn inhibitors Targeted Patient Pool
• Therapeutic Approaches
• FcRn Inhibitor Pipeline Analysis
• FcRn Inhibitor Market Size and Trends
• Existing and future Market Opportunity

FcRn Inhibitor Report Key Strengths

• Eleven years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

FcRn Inhibitor Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What was the FcRn inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2036? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2036?
• Which is the most lucrative market for FcRn inhibitors?
• What are the pricing variations among different geographies for approved therapies?
• How the reimbursement landscape has for FcRn inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with FcRn inhibitors? What will be the growth opportunities across the 7MM for the patient population of FcRn inhibitors?
• What are the key factors hampering the growth of the FcRn inhibitor market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for FcRn inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the FcRn inhibitor market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of FcRn Inhibitor

4. Key Events

5. Epidemiology Market Forecast Methodology

6. FcRn Inhibitor Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2025
• 6.2. Market Share (%) Distribution by Therapies in 2036
• 6.3. Market Share (%) Distribution by Indications in 2025
• 6.4. Market Share (%) Distribution by Indications in 2036

7. FcRn Inhibitor: Background and Overview

• 7.1. Introduction
• 7.2. Potential of FcRn Inhibitors in Different Indications
• 7.3. Clinical Applications of FcRn Inhibitors

8. Epidemiology and Patient Population in Different Indications

• 8.1. Assumptions and Rationale
• 8.2. Total Incident Cases of Selected Indications for FcRn Inhibitors

9. Target Patient Pool

• 9.1 Key Findings
• 9.2 Assumptions and Rationale: 7MM
• 9.3 Epidemiology Scenario in the 7MM
  • 9.3.1 Total Eligible Patient Pool by Indication for FcRn Inhibitor in the 7MM
  • 9.3.2 Total Treatable Cases by Indication for FcRn Inhibitor in the 7MM

10. Marketed Therapies

• 10.1. Key Competitors
• 10.2. VYVGART (Efgartigimod): Argenx
  • 10.2.1. Product Description
  • 10.2.2. Regulatory milestones
  • 10.2.3. Other developmental activities
  • 10.2.4. Clinical development
  • 10.2.5. Safety and efficacy
• 10.3. RYSTIGGO (rozanolixizumab-noli): UCB Biopharma
  • 10.3.1. Product Description
  • 10.3.2. Regulatory milestones
  • 10.3.3. Other developmental activities
  • 10.3.4. Clinical development
  • 10.3.5. Safety and efficacy

11. Emerging Therapies

• 11.1. Key Competitors
• 11.2. Batoclimab: Immunovant
  • 11.2.1. Product Description
  • 11.2.2. Other developmental activities
  • 11.2.3. Clinical development
  • 11.2.4. Safety and efficacy
• 11.3. Nipocalimab: Johnson & Johnson Innovative Medicine
  • 11.3.1. Product Description
  • 11.3.2. Other developmental activities
  • 11.3.3. Clinical development
  • 11.3.4. Safety and efficacy

12. FcRn Inhibitor: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Sizes of FcRn Inhibitors by Indications in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of FcRn Inhibitors in the United States
  • 12.6.2. Market Size of FcRn Inhibitors by Indication in the United States
  • 12.6.3. Market Size of FcRn Inhibitors by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of FcRn Inhibitors in EU4 and the UK
  • 12.7.2. Market Size of FcRn Inhibitors by Indications in EU4 and the UK
  • 12.7.3. Market Size of FcRn Inhibitors by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of FcRn Inhibitors in Japan
  • 12.8.2. Market Size of FcRn Inhibitor by Indications in Japan
  • 12.8.3. Market Size of FcRn Inhibitors by Therapies in Japan

13. SWOT Analysis

14. KOL Views

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight